[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![overnight_stock Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1941151648589434880.png) overnightstocks.com [@overnight_stock](/creator/twitter/overnight_stock) on x XXX followers
Created: 2025-07-23 15:37:27 UTC

$REPL | Replimune rebounds despite FDA rejection and multiple downgrades | via

• Shares plummeted -XX% on Tuesday after FDA rejected RP1 application for advanced melanoma (combo with $BMY’s Opdivo)
• Wednesday rebound: +24.24% despite analyst downgrades
• BMO: Downgrade to Underperform, PT cut to $X
• Barclays: Downgrade to Equal Weight, PT slashed to $X (from $17)
• H.C. Wainwright: Downgrade to Neutral from Buy
• Concerns over funding and need to rerun clinical trials per FDA feedback

![](https://pbs.twimg.com/media/GwjYaBoWgAAEIUX.png)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948044796523585938/c:line.svg)

**Related Topics**
[repl](/topic/repl)
[$barcl](/topic/$barcl)
[rating agency](/topic/rating-agency)
[$bmys](/topic/$bmys)
[combo](/topic/combo)
[stocks](/topic/stocks)
[replimune](/topic/replimune)
[$repl](/topic/$repl)

[Post Link](https://x.com/overnight_stock/status/1948044796523585938)